Pet Peptide Academy — Evidence-Based Protocols for Veterinary Oncology & Recovery

How to Read This Site — Evidence Grading System

Every compound on this site is graded for evidence quality using a traffic light system. These grades reflect the strength of published, peer-reviewed evidence — not our opinion on whether a compound works. We believe transparent uncertainty builds more trust than false confidence.

Good Evidence

Multiple studies in the target species or approved for use in 2+ countries. Published clinical data with known safety profile. Does not mean "proven" — means the evidence base is meaningfully established.

Emerging Evidence

Some published data supports this use, but evidence may be limited to one species, one study, preclinical models, or extrapolated from human/rodent data using allometric scaling. Promising but incomplete.

Preliminary / In Vitro Only

Evidence is limited to cell culture, rodent models, or mechanistic reasoning. No companion animal data exists. Highly experimental — included for completeness, not endorsement.

Regulatory badges indicate each compound's current FDA status. "FDA-Approved" means the drug is approved for some veterinary use (not necessarily oncology). "Research-Use Only" means no FDA approval pathway exists. "FDA Category 2" means the compound is currently prohibited from human compounding but has no veterinary-specific restriction. All compound pages include species-specific evidence notes where canine, feline, or equine data differs.

Key Terms — A Quick Reference

VCPR
Veterinarian-Client-Patient Relationship — the legal requirement for a vet to know your animal before prescribing or directing treatment.

AMDUCA
Animal Medicinal Drug Use Clarification Act — federal law allowing vets to use approved drugs for unapproved ("off-label") purposes under a valid VCPR.

BSA Scaling
Body Surface Area scaling — the standard method for converting drug doses between species based on metabolic rate, not just body weight.

Allometric
Scaling that accounts for how biological processes change with body size. Larger animals metabolize drugs differently than smaller ones.

Km Factor
Species-specific conversion constant used in BSA scaling. Dog = 20, Cat = 12, Horse = 36.2. Higher Km = slower relative metabolism per kg.

Off-Label / Extralabel
Using an FDA-approved drug for a purpose, species, or dose not listed on its label. Legal only under veterinary supervision via AMDUCA.

SQ / SubQ
Subcutaneous — injection under the skin into the fat layer. The most common route for peptide administration in pets.

IM
Intramuscular — injection directly into muscle tissue. Used for some peptides, particularly TB-500 in horses.

In Vitro / In Vivo
In vitro = studied in a lab dish/test tube. In vivo = studied in a living animal. In vivo evidence is much stronger.

Reconstitution
Mixing a freeze-dried (lyophilized) peptide powder with sterile water to create an injectable solution.

Choose Your Academy

Which Species Protocols Are Available?

Select a species to explore detailed protocols for peptides and repurposed drugs, with dosing tables, protocol timelines, and scientific evidence.

Canine

Canine Academy

Complete protocols for dogs of all weight classes — from toy breeds to giant breeds.

9 Compounds4 Combinations9 Protocols

Feline

Feline Academy

Feline-specific dosing with FIV/FeLV support, FISS awareness, and copper toxicity guidance.

9 Compounds4 Combinations9 Protocols

Equine

Equine Academy

Performance and recovery protocols with competition/doping awareness and BSA-scaled dosing.

9 Compounds4 Combinations9 Protocols

Canine Academy

Canine Protocols

Complete dosing protocols for all canine weight classes. Click any compound to expand dosing details, protocol timelines, and evidence.

01

BPC-157

Body Protection Compound-157 — The only peptide with published canine PK data

EmergingFDA Cat. 2 · Vet unrestricted Regen Wound

Investigated Mechanisms

Investigated for promoting healing through increased blood vessel growth and inflammation reduction. May protect the gut lining. First compound in this resource with a published canine PK study showing 45–51% absorption when injected. No toxic dose has been identified in preclinical animal studies (Xu 2020).

Weight Class	Dose	How Often	Duration	Best For
<10 kg (toy/small)	20–100 mcg/day	Once daily	2–4 weeks	GI issues, joint injuries, post-surgical
10–35 kg (medium)	50–250 mcg/day	Once daily	2–8 weeks	Tendon/ligament, GI protection, wounds
>35 kg (large/giant)	100–500 mcg/day	Once daily	2–8 weeks	Orthopedic recovery, chronic conditions

📋 Example Protocol — See Cycling Guide for break schedules

Example Research Protocol — Wolverine Protocol (BPC-157 + TB-500)

1

Day 1 — Initial Load

Begin Loading Phase

🐾 Owner Observation

May notice slight lethargy for first 24 hours. Normal eating and drinking behavior should continue.

🔬 Biological Marker

Baseline CBC/Chem panel. Document injection sites. BPC-157 peak plasma at 6–8 min IM, t½ <30 min.

2

Week 2 — Assessment

Early Response Evaluation

🐾 Owner Observation

Increased willingness to bear weight. May show more energy on walks. Improved appetite.

🔬 Biological Marker

Palpate injury site — expect reduced swelling and heat. Assess gait score improvement. Check injection site rotation.

3

Week 4 — Transition

Maintenance Phase Decision

🐾 Owner Observation

Significant mobility improvement. Playing, running, climbing stairs. Near-normal activity levels.

🔬 Biological Marker

Reduction in inflammatory markers. Imaging (if applicable) may show tissue consolidation. Transition TB-500 to maintenance dose.

4

Week 8 — Completion

Protocol Complete

🐾 Owner Observation

Full return to normal activity. Sustained improvement in quality of life.

🔬 Biological Marker

Follow-up imaging confirms tissue repair. Gait analysis normalized. Consider maintenance BPC-157 (3×/wk) for chronic conditions.

Investigated Mechanisms (Clinical Detail)

Investigated for angiogenesis promotion via VEGF/VEGFR2 upregulation, NO/eNOS system modulation, and tendon-to-bone healing acceleration. PK in beagles: 45–51% IM bioavailability, t½ <30 min, linear PK at 6–150 mcg/kg. Cmax at 6–8 min IM. Main excretion: urine and bile. No lethal dose found at repeated doses up to 2 mg/kg.

Parameter	Dose	Route	Frequency	Duration	Indications	Ref
Clinical equivalent	6 mcg/kg/day	SQ IM	Once daily	2–4 wk (acute) / 4–8 wk (chronic)	Tissue repair, GI protection, wound healing, joints, post-surgical	1,2,3,4
Full range	2–10 mcg/kg/day	SQ IM	Once daily	2–8 weeks	Start conservative, titrate up	1,2,5

Key Evidence

He et al. 2022 (PMID 36588722): First canine PK study. Beagle clinical dose 6 mcg/kg IM. Linear PK at 6–150 mcg/kg. Well-tolerated 7-day repeated dosing at 30 mcg/kg.
Xu et al. 2020 (PMID 32334036): Comprehensive safety — no lethal dose in dogs, no genotoxicity, no teratogenicity.
Vasireddi et al. 2025 (PMC12313605): Systematic review — 544 articles screened, BPC-157 enhances GHR expression, angiogenesis pathways.

02

TB-500

Thymosin β4 fragment — most established veterinary research compound, equine studies since early 2000s

EmergingFDA Cat. 2 · Racing banRegenWound

Investigated Mechanisms

Active fragment LKKTETQ is associated with actin binding, cell migration, and wound repair in preclinical models. Investigated for promoting angiogenesis, collagen deposition, and inflammation reduction.

Dose	Route	Loading	Maintenance	Duration
0.1–0.25 mg/kg/wk ~2–5 mg/wk med dog	SQ IM	1–2×/wk for 2–4 wk	Half dose 1×/wk	Loading: 2–4 wk / Maint: 4–8 wk

Contraindicated with Active Cancer

TB-500 is associated with promoting angiogenesis & cell migration in preclinical models. Screen all patients before initiating. Banned in competitive racing.

📋 Example Protocol — See Cycling Guide for break schedules

Example Research Protocol — TB-500

1

Weeks 1–2 — Loading Phase

Twice Weekly Loading Dose

🐾 Owner Observation

May see mild swelling at injection site (normal). Monitor energy levels and appetite — should remain stable. Note baseline mobility limitations.

🔬 Biological Marker

Full dose 0.1–0.25 mg/kg 2×/wk SQ. Document baseline gait score and range of motion. Actin-binding and cell migration effects are reported to begin within 48 hrs in preclinical studies.

2

Weeks 3–4 — Transition

Reduce to Maintenance

🐾 Owner Observation

Visible improvement in mobility. Increased willingness to play, walk, climb stairs. Wound closure accelerating if treating soft tissue.

🔬 Biological Marker

Transition to half dose 1×/wk. Assess collagen deposition and inflammation reduction. Re-evaluate gait score improvement.

3

Weeks 5–8 — Maintenance

Sustained Recovery

🐾 Owner Observation

Continued improvement. Coat quality may improve. Near-normal activity levels for most patients. Monitor for any lumps at injection sites.

🔬 Biological Marker

Maintenance dose 1×/wk. Follow-up imaging at Week 6 if applicable. Taper off or continue based on response. No withdrawal syndrome has been reported.

03

Thymosin Alpha-1

Approved in 35+ countries as Zadaxin® — most established evidence base among listed compounds

Good EvidenceZadaxin® 35+ countriesImmuneOncology

Investigated Mechanisms

Reported to bind TLR2/TLR9, activating NK cells, CD4+/CD8+ T-cells, and IFN-γ/IL-2 production in published studies. Immunomodulatory — investigated for rebalancing rather than suppressing or overstimulating immune function. Studied as potential oncology adjunct (PTEN/PI3K/Akt/mTOR pathway modulation observed in vitro).

Dose	Route	Frequency	Duration	Indications
50–100 mcg/kg	SQ	2–3× weekly	4–12 wk or ongoing	Investigational oncology adjunct, chronic infections, immune deficiency, vaccine enhancement

Research Note

Published data suggests TA1 may enhance immune surveillance without appearing to promote tumor growth based on published data — one of the exceptions to the cancer contraindication common among growth-promoting peptides. Investigated in combination with PNC-27 for immune-oncology approaches.

📋 Example Protocol — See Cycling Guide for break schedules

Example Research Protocol — Thymosin Alpha-1 (Immune Modulation)

1

Week 1 — Immune Priming

Begin 3×/Week Protocol

🐾 Owner Observation

No visible side effects expected. Monitor appetite and energy. Some dogs may show mild lethargy on injection days — transient and normal.

🔬 Biological Marker

Baseline CBC with differential, lymphocyte subsets if available. 50–100 mcg/kg SQ 3×/wk. TLR2/TLR9 activation is reported to begin within 24 hrs, with NK cell upregulation observed by Day 3–5 in published studies.

2

Weeks 2–4 — Immune Activation

CD4+/CD8+ T-Cell Response Building

🐾 Owner Observation

For cancer patients: tumor growth stabilization or slowing may be observed. For immune-deficient: improved energy, appetite, and activity levels.

🔬 Biological Marker

IFN-γ and IL-2 production expected to be increasing. Repeat CBC at Week 4 — expect improved lymphocyte counts. Continue 2–3×/wk SQ. If combining with PNC-27, stagger injections.

3

Weeks 4–12 — Sustained Response

Maintenance & Assessment

🐾 Owner Observation

Stabilized or improved condition. Quality of life improvements visible. Monitor for any unusual lumps, changes in behavior, or loss of appetite.

🔬 Biological Marker

Continue 2×/wk. For oncology: imaging at Week 8 for tumor response. PTEN/PI3K/Akt/mTOR pathway modulation expected to be ongoing. May continue long-term for chronic conditions. No cumulative toxicity has been reported.

04

GHK-Cu

Copper Tripeptide — modulates 4,000+ genes, published canine wound study

EmergingResearch compoundWoundRegen

Dose	Route	Frequency	Duration	Indications
0.5–2 mg/day or topical 2×/day	SQ IM Topical	Daily (inj) / 2× daily (topical)	4–8 wk (inj) / ongoing (topical)	Wound healing, skin/coat, post-surgical, joints

Copper Note

Bedlington Terriers and some Labrador lines carry genetic copper storage disease. Monitor hepatic function. Topical preferred for localized conditions.

📋 Example Protocol — See Cycling Guide for break schedules

Example Research Protocol — GHK-Cu (Injectable + Topical)

1

Days 1–7 — Initiation

Begin Daily Protocol

🐾 Owner Observation

For topical: apply thin layer to wound/skin area 2×/day. For injectable: SQ daily. No visible changes expected yet. Monitor for any skin irritation at topical sites.

🔬 Biological Marker

GHK-Cu is reported to modulate 4,000+ genes related to tissue remodeling. Collagen synthesis upregulation is reported to begin within 48–72 hrs. Check baseline liver values (copper metabolism).

2

Weeks 2–4 — Active Remodeling

Tissue Regeneration Phase

🐾 Owner Observation

Wounds show accelerated closure. Coat quality improving — thicker, shinier fur growth. Skin lesions reducing. Post-surgical incisions healing faster.

🔬 Biological Marker

Collagen I/III deposition and decorin/glycosaminoglycan synthesis expected to be elevated. Re-assess wound bed at Week 3. Continue daily or reduce to 3×/wk based on response.

3

Weeks 4–8 — Completion

Taper or Transition to Topical-Only

🐾 Owner Observation

Significant wound healing or coat improvement. For chronic skin conditions, topical maintenance may continue long-term.

🔬 Biological Marker

Discontinue injectable after 4–8 wk. Check liver values if injectable was used >4 wk. Topical may continue indefinitely for chronic dermatologic conditions. No systemic copper accumulation concern at topical doses.

05

PNC-27

Investigated for selective tumor targeting via membrane HDM-2 binding

PreliminaryResearch-use onlyOncology

Dose	Route	Frequency	Duration	Indications
0.5–2 mg/kg	SQ Intratumoral	2–3× weekly	8–12+ weeks	Investigational — HDM-2 overexpressing tumors under study

Level V Evidence

In vitro/rodent only. No companion animal trials. Intratumoral injection likely most effective. Highly experimental.

📋 Example Protocol — See Cycling Guide for break schedules

Example Research Protocol — PNC-27 (Investigational)

1

Week 1 — Baseline & Initiation

Begin 2–3×/Week Protocol

🐾 Owner Observation

Photograph and measure all visible tumors. Note appetite, energy levels, and pain behaviors. May see mild injection site tenderness — transient.

🔬 Biological Marker

Full staging: imaging, CBC, chemistry panel. 0.5–2 mg/kg SQ or intratumoral 2–3×/wk. PNC-27 has been reported to bind membrane HDM-2 on cancer cells, potentially leading to selective pore formation and necrosis in preclinical models. Normal cells appear to be unaffected.

2

Weeks 4–6 — First Assessment

Tumor Response Evaluation

🐾 Owner Observation

Tumor may soften, shrink, or ulcerate (sign of necrosis — can be a positive response). Energy and appetite should be stable or improving. Report any weight loss immediately.

🔬 Biological Marker

Re-image tumors. Compare dimensions. Histologically, tumor necrosis is expected response. If combining with TA1: NK/CD8+ cell counts should be rising. Adjust dose based on response.

3

Weeks 8–12+ — Ongoing Assessment

Continue or Adjust Protocol

🐾 Owner Observation

Quality of life is the primary metric. Sustained appetite, activity, and comfort indicate positive response. Document changes weekly with photos.

🔬 Biological Marker

Continue 2–3×/wk if response is positive. Full restaging at Week 12. May combine with TA1 (immune) + ivermectin (investigational oncology adjunct) for comprehensive protocol. No cumulative toxicity has been reported at therapeutic doses.

06

IGF-1 LR3

Extended half-life growth factor (~20–30 hrs vs native ~20 min)

PreliminaryResearch-use onlyGrowth

Dose	Route	Frequency	Duration	Indications
1–4 mcg/kg/day	SQ IM	Once daily	4–6 wk (cycle on/off)	Muscle wasting, post-surgical recovery, sarcopenia

Contraindication

Contraindicated with active cancer. Monitor blood glucose. Cycle 4 wk on / 4 wk off. Level V evidence.

📋 Example Protocol — See Cycling Guide for break schedules

Example Research Protocol — IGF-1 LR3 (Growth Factor Cycling)

1

Week 1 — Start Low

Conservative Initiation

🐾 Owner Observation

No visible changes expected. Monitor for lethargy, tremors, or unusual hunger (potential hypoglycemia signs). Feed normally — do not fast around injection times.

🔬 Biological Marker

Start at 1 mcg/kg/day SQ. Check fasting glucose at baseline and Day 7. Extended t½ (~20–30 hrs) vs native IGF-1 (~20 min) means sustained signaling.

2

Weeks 2–4 — Active Phase

Titrate to Target Dose

🐾 Owner Observation

Improved muscle mass and definition in wasting patients. Increased energy and activity. Appetite increase is normal. Monitor weight weekly.

🔬 Biological Marker

Increase to 2–4 mcg/kg/day if tolerated. Muscle protein synthesis and satellite cell activation expected during this phase. Check glucose at Week 2 and 4. Assess for any organ hypertrophy.

3

Week 5+ — Cycle Off

Mandatory Off-Cycle (4 weeks)

🐾 Owner Observation

Gains from first cycle should be maintained during off period. Continue normal exercise and nutrition. Note any regression in muscle mass.

🔬 Biological Marker

Stop IGF-1 LR3 for 4 weeks. Allow IGF-1 receptor sensitivity to normalize. Repeat glucose check. May resume for another 4-week cycle if needed. Max 3 cycles recommended.

07

MGF (IGF-1Ec)

Mechano Growth Factor — inject near injury site

PreliminaryResearch-use onlyGrowth

Dose	Route	Frequency	Duration	Indications
2–5 mcg/kg/day	IM (near injury)	Daily or EOD	4–6 weeks	Muscle repair, post-injury recovery, muscle loss

📋 Example Protocol — See Cycling Guide for break schedules

Example Research Protocol — MGF (Localized Muscle Repair)

1

Week 1 — Localized Initiation

Inject Near Injury Site

🐾 Owner Observation

IM injection should be administered as close to the injury/muscle area as practical. Mild soreness at injection site is normal. Restrict activity during treatment.

🔬 Biological Marker

2–5 mcg/kg/day IM near target muscle. MGF is reported to activate satellite cells for muscle regeneration. Short t½ (~15 min) means localized effect — proximity to injury matters. Aspirate before injecting.

2

Weeks 2–4 — Active Regeneration

Muscle Fiber Repair Phase

🐾 Owner Observation

Improved limb use and weight bearing. Reduced pain behaviors. Gradual return of strength. Controlled leash walks OK — no off-leash or high-impact activity.

🔬 Biological Marker

Satellite cell proliferation and myoblast differentiation expected during this phase. May combine with BPC-157 (SQ) for complementary tissue repair. Assess muscle mass and symmetry at Week 3.

3

Weeks 4–6 — Completion

Taper and Rehabilitate

🐾 Owner Observation

Near-normal muscle function expected. Gradual return to regular activity. Physical rehabilitation exercises recommended during this phase.

🔬 Biological Marker

Reduce to EOD for final 2 weeks, then discontinue. Muscle protein synthesis should sustain gains after cessation. Follow-up assessment at Week 8. PT/rehab recommended concurrent.

08

Fenbendazole

Repurposed benzimidazole anthelmintic — investigated for microtubule disruption, p53 activation, glucose metabolism interference

EmergingFDA-approved anthelminticOncology

Investigated Mechanisms

Fenbendazole (Panacur) has been observed to disrupt microtubule polymerization by binding β-tubulin in preclinical studies — a mechanism shared with chemotherapy agents vincristine and paclitaxel. In vitro research also reports p53 activation, GLUT1 transporter and hexokinase II inhibition (potentially interfering with cancer cell glucose metabolism), G2/M cell cycle arrest induction, and cancer stem cell targeting. Multiple independent pathways are under investigation, which may reduce the likelihood of resistance development.

Dose	Route	Schedule	Duration	Indications
50 mg/kg/day	Oral	3 days on / 4 days off	4–12+ weeks	Investigational — all solid tumor types under study

📋 Example Protocol — See Cycling Guide for break schedules

Example Research Protocol — Fenbendazole (Oral Investigational)

1

Week 1 — Initiation

Begin 3-On/4-Off Cycle

🐾 Owner Observation

Administer orally with a fatty meal (improves absorption — fenbendazole is highly lipophilic with poor water solubility). Monitor appetite, stool quality, and energy. Most dogs tolerate well with no visible side effects.

🔬 Biological Marker

50 mg/kg/day oral for 3 consecutive days, then 4 days off. Baseline CBC, liver panel, chemistry. Fenbendazole has low oral bioavailability in dogs — systemic concentration is modest but GI tumor exposure is direct. LD50 >10 g/kg in rodents (very wide safety margin).

2

Weeks 2–4 — Assessment

Monitor Bloodwork & Tumor Response

🐾 Owner Observation

Continue weekly cycling. Watch for any appetite changes, lethargy, or pale gums (signs of bone marrow suppression — rare but reported with extended daily dosing). Report immediately if noted.

🔬 Biological Marker

Repeat CBC at Week 2 and 4 — monitor for pancytopenia (bone marrow suppression reported in dogs receiving continuous daily dosing beyond labeled 3-day courses). Liver values should remain stable. Tumor imaging at Week 4 if applicable.

3

Weeks 4–12+ — Ongoing

Continue If Tolerated & Responding

🐾 Owner Observation

Quality of life is the primary endpoint. Sustained appetite, activity, and comfort indicate good tolerance. The 4-day weekly break allows liver recovery and reduces bone marrow stress.

🔬 Biological Marker

Continue 3-on/4-off cycling. Monthly CBC and liver panel. Can combine with TA1 (immune support) and PNC-27 (investigated for selective tumor targeting). Do NOT combine with vincristine or paclitaxel (overlapping microtubule mechanism — additive toxicity risk). May add curcumin and vitamin E as adjuncts per Tippens protocol.

Safety Warning

Long-term daily dosing beyond the labeled 3-day deworming course is experimental. Bone marrow suppression (pancytopenia) has been documented in dogs receiving fenbendazole at extended daily doses. The 3-on/4-off cycling schedule is designed to mitigate this risk. Monitor CBC regularly. Liver injury has been reported in human self-administration cases. This is a repurposed drug — no veterinary oncology trials have been completed.

09

Ivermectin

Nobel Prize-winning antiparasitic — investigated for Wnt/β-catenin, Akt/mTOR, and PAK1 pathway modulation with published in vitro canine data

EmergingFDA-approved antiparasiticOncology

Investigated Mechanisms

Ivermectin has been investigated for modulating multiple signaling pathways in preclinical cancer models: Wnt/β-catenin (observed to interfere with β-catenin nuclear translocation), Akt/mTOR (reported to suppress survival signaling), and PAK1 kinase (a regulator at the intersection of multiple tumorigenic pathways). Also studied for autophagy induction, cancer stem cell targeting potential, multidrug resistance reversal, and potential angiogenesis inhibition. A published in vitro study using canine mammary tumor cells reported dose-dependent growth inhibition and G1/S cell cycle arrest (Zhu et al. 2019, PMC6679554).

Dose	Route	Frequency	Duration	Indications
0.3–0.6 mg/kg/day	Oral	Daily or 5 days on / 2 days off	4–12+ weeks	Investigational — mammary, lymphoma, melanoma, solid tumors under study

📋 Example Protocol — See Cycling Guide for break schedules

Example Research Protocol — Ivermectin (Oral Investigational)

1

Week 1 — Conservative Start

Low Dose Initiation

🐾 Owner Observation

Start at 0.3 mg/kg orally daily. Give with food. Monitor for neurological signs: unsteadiness, dilated pupils, drooling, tremors. These are rare at therapeutic doses but report immediately. Most dogs tolerate well.

🔬 Biological Marker

Baseline CBC, liver panel. Test for MDR1 gene mutation in susceptible breeds (Collies, Australian Shepherds, Shelties, etc.) BEFORE initiating — ivermectin toxicity risk is dramatically elevated in MDR1-mutant dogs. Start 0.3 mg/kg/day oral.

2

Weeks 2–4 — Titrate & Monitor

Increase to Target Dose

🐾 Owner Observation

If tolerated, may increase to 0.6 mg/kg. Continued normal appetite, energy, and behavior expected. Ivermectin is highly lipophilic — taking with a fatty meal improves absorption.

🔬 Biological Marker

Wnt/β-catenin suppression and cancer stem cell inhibition have been reported as dose-dependent in published studies. Published canine mammary data showed significant growth inhibition at 8–16 µM in vitro. Repeat CBC/liver at Week 2. Tumor assessment at Week 4.

3

Weeks 4–12+ — Ongoing

Long-Term Adjunct Protocol

🐾 Owner Observation

Ivermectin is generally well-tolerated long-term in non-MDR1 dogs (it has been used as a daily heartworm preventive for decades). Quality of life assessment weekly. Can combine with TA1 + PNC-27 or fenbendazole.

🔬 Biological Marker

Monthly monitoring. Ivermectin has been investigated for multidrug resistance reversal — may enhance efficacy of concurrent chemotherapy if used. Complementary with fenbendazole (different microtubule mechanisms). Do not exceed 0.6 mg/kg/day for cancer protocols. The published study (Zhu 2019) reports WNT pathway modulation in canine mammary cells with no hepatic/renal toxicity in xenograft models.

MDR1 / Breed Warning

MANDATORY MDR1 gene test before initiating ivermectin at investigational oncology doses. Breeds with known MDR1 sensitivity: Collies, Australian Shepherds, Shetland Sheepdogs, Old English Sheepdogs, and mixed breeds with herding lineage. MDR1-mutant dogs cannot safely metabolize ivermectin at these doses — neurotoxicity can be fatal. Test is a simple cheek swab available through Washington State University or commercial labs.

Feline Academy

Feline Protocols

Feline-specific dosing with considerations for copper sensitivity, FISS awareness, FIV/FeLV support, and allometric scaling (Km cat=12).

01

BPC-157

2–5 mcg/kg/day SQ — extrapolated from canine PK (Km cat=12, dog=20)

EmergingFDA Cat. 2 · Vet unrestrictedRegen

Investigated Mechanisms

Investigated for promoting healing through increased blood vessel growth (VEGF/eNOS pathway) and inflammation reduction. May protect the gut lining and accelerate tissue repair based on preclinical data. Feline dosing scaled from canine PK data using allometric BSA conversion (Km cat=12, dog=20). Very safe — no toxic dose established even at high amounts.

Dose	Route	Frequency	Duration	Indications
2–5 mcg/kg/day	SQ	Once daily	2–4 weeks	GI issues, tissue repair, inflammatory conditions, post-surgical

Note

Limited feline-specific data. Start conservative. Injectable preferred for systemic effects.

📋 Example Protocol — See Cycling Guide for break schedules

Example Research Protocol — Feline BPC-157

1

Days 1–3 — Initiation

Conservative Start

🐾 Owner Observation

SQ injection — lateral body wall or flank fold. Very small volume (0.1–0.3 mL). Cat should tolerate well. Monitor eating, litter box, and behavior. No changes expected yet.

🔬 Biological Marker

Start at 2 mcg/kg/day SQ. Feline dose extrapolated via Km scaling (cat Km=12, dog Km=20). Peak plasma expected at 6–8 min IM. t½ <30 min but tissue effects persist longer.

2

Week 1–2 — Early Response

Tissue Repair Initiating

🐾 Owner Observation

For GI issues: improved appetite and reduced vomiting. For injuries: reduced guarding, more willingness to move and jump. Increased grooming (sign of comfort).

🔬 Biological Marker

May increase to 5 mcg/kg if tolerated and indicated. VEGF/eNOS pathway activation. Gut mucosal healing for GI patients. Rotate injection sites — track in chart.

3

Weeks 2–4 — Completion

Assess & Taper

🐾 Owner Observation

Near-normal activity levels. GI cats eating well, consistent stool quality. Surgical/injury patients showing healed tissue. Can taper to EOD for final week.

🔬 Biological Marker

Re-assess at Week 2. If acute condition resolved, may discontinue. For chronic conditions, continue 2–4 more weeks at reduced frequency (3×/wk). Safe for extended use — no toxic dose found in studies.

02

TB-500

0.5–1 mg 2×/wk loading, 0.5 mg 1×/wk maintenance

EmergingFDA Cat. 2 · Racing banRegen

Investigated Mechanisms

Active fragment LKKTETQ is associated with actin binding, cell migration, and wound repair in preclinical models. Investigated for promoting angiogenesis, collagen deposition, and inflammation reduction. Same proposed mechanism as canine but lower doses due to smaller body mass. Avoid lateral body wall injections near interscapular region (FISS risk).

Loading	Maintenance	Route	Duration	Indications
0.5–1 mg 2×/wk	0.5 mg 1×/wk	SQ	Load: 2 wk / Maint: 4–6 wk	Tissue repair, wound healing, inflammation

Contraindication

Avoid with active tumors. Associated with promoting angiogenesis & cell migration in preclinical studies.

📋 Example Protocol — See Cycling Guide for break schedules

Example Research Protocol — Feline TB-500

1

Weeks 1–2 — Loading

SQ Loading Phase

🐾 Owner Observation

SQ injection in lateral body wall or flank. Small volume (0.1–0.3 mL). Monitor for injection site swelling. Cat should remain comfortable — reduced activity during healing is normal.

🔬 Biological Marker

0.5–1 mg 2×/week SQ. Lateral trunk only — avoid interscapular (FISS risk). Actin-mediated cell migration has been observed beginning within 24–48 hrs in preclinical studies. Track injection sites in rotation chart.

2

Weeks 3–4 — Maintenance

Reduced Frequency

🐾 Owner Observation

Improved mobility, less guarding of injury. Cat may resume jumping and grooming. Continue monitoring injection sites for lumps (FISS screening — any lump >2cm or persisting >3 months requires immediate vet evaluation).

🔬 Biological Marker

Reduce to 0.5 mg 1×/week. Collagen cross-linking and tissue remodeling are expected during this phase. May combine with BPC-157 for complementary effect (different injection sites, different days).

3

Weeks 4–6 — Completion

Taper & Assess

🐾 Owner Observation

Near-normal activity. Injury site should be non-painful. Can taper to every 10 days for final 2 weeks before discontinuing.

🔬 Biological Marker

Re-assess at Week 4. If resolved, taper and discontinue. For chronic conditions, may extend maintenance. Contraindicated with active tumors — associated with promoting angiogenesis and cell migration in preclinical models.

03

Thymosin Alpha-1

Investigated for immune modulation in feline oncology & FIV/FeLV support

Good EvidenceZadaxin® 35+ countriesImmuneOncology

Investigated Mechanisms

Reported to bind TLR2/TLR9, activating NK cells, CD4+/CD8+ T-cells, dendritic cells, and IFN-γ/IL-2 production in published studies. Immunomodulatory — investigated for rebalancing rather than suppressing or overstimulating immune function. Of particular research interest for FIV/FeLV-positive cats where immune function is compromised. Published data suggests compatibility with oncology cases — may enhance immune surveillance potential without appearing to promote tumor growth based on published data.

Dose	Route	Frequency	Duration	Indications
25–75 mcg/kg	SQ	2–3× weekly	4–12 wk or ongoing	Immune modulation research, FIV/FeLV investigational adjunct, chronic viral infections

Feline Investigational Oncology Protocol

TA1 + PNC-27 are investigated for immune-oncology approaches. TA1 is reported to activate NK cells & CD8+ T-cells in published studies. PNC-27 has been observed to selectively target cancer cells in vitro. Neither appears to promote tumor growth based on published data. For aggressive cases, ivermectin may be added (Investigational Triple Protocol — highly experimental).

📋 Example Protocol — See Cycling Guide for break schedules

Example Research Protocol — Feline Thymosin Alpha-1 (Standalone Immune Support)

1

Week 1 — Immune Priming

Begin TA1

🐾 Owner Observation

SQ injection 2–3× per week in lateral body wall (avoid interscapular). Monitor appetite, energy level, and litter box. FIV/FeLV-positive cats may show gradual improvement in chronic symptoms.

🔬 Biological Marker

25–75 mcg/kg SQ 2–3×/week. TA1 is reported to activate dendritic cells, NK cells, and CD8+ T-cells via TLR2/TLR9. Immune priming has been reported to begin within 48 hours. Particularly valuable for immunocompromised cats (FIV/FeLV). No desensitization has been observed at therapeutic doses.

2

Weeks 2–4 — Immune Activation

Full Response

🐾 Owner Observation

Improved appetite and energy. Fewer secondary infections if immunocompromised. Better wound healing. Cat may be more social and active. Continue monitoring for any injection site reactions.

🔬 Biological Marker

Continue 2–3×/week. Recheck CBC with differential at Week 2 — lymphocyte profiles should improve. For cancer patients: TA1 may enhance immune surveillance potential. Combine with PNC-27 for immune-oncology approach. Safe long-term — approved in 35+ countries as Zadaxin® in humans.

3

Weeks 4–12+ — Maintenance

Ongoing or Taper

🐾 Owner Observation

For acute illness: taper and discontinue once resolved. For chronic conditions (FIV/FeLV, cancer): may continue long-term per vet guidance. Monitor overall condition.

🔬 Biological Marker

May reduce to 1–2×/week for maintenance. Monthly CBC monitoring. For feline cancers: pair with Investigational Triple Protocol (TA1 + PNC-27 ± Ivermectin) for comprehensive immune-oncology. TA1 is one of the safest compounds in the protocol — no tumor promotion has been observed in published data.

📋 Example Protocol — See Cycling Guide for break schedules

Example Research Protocol — Feline Investigational Triple Protocol (TA1 + PNC-27 ± Ivermectin)

1

Week 1 — Staging & Start TA1

Immune Priming Phase

🐾 Owner Observation

Begin TA1 alone first. SQ injection — lateral body wall (NOT interscapular). Monitor eating, litter box use, and energy. Cats may be quieter on injection days — normal.

🔬 Biological Marker

Full staging: bloodwork, imaging, FIV/FeLV status. TA1 25–75 mcg/kg SQ 3×/wk. Rotate injection sites aggressively (FISS awareness). NK cell activation has been reported to begin within 48 hrs in published studies.

2

Week 2 — Add PNC-27

Dual Immune-Oncology

🐾 Owner Observation

Now 2 separate injections on different days. Stagger: Mon/Wed/Fri TA1, Tue/Thu PNC-27. Watch for tumor softening or size changes. Maintain food intake — critical for cats.

🔬 Biological Marker

Add PNC-27 at 0.25–1 mg/kg SQ or intratumoral 2–3×/wk. PNC-27 is investigated for targeting membrane HDM-2 on cancer cells. TA1 is reported to support immune-mediated processing of lysed tumor debris. Monitor weight weekly — >5% loss requires intervention.

3

Week 4 — First Assessment

Response Evaluation

🐾 Owner Observation

Quality of life scoring: appetite, grooming, social interaction, pain level. Tumors may soften, shrink, or ulcerate (necrosis = positive sign). Document with photos.

🔬 Biological Marker

Re-image tumors. Repeat CBC with differential — lymphocyte counts should be improving. If adding ivermectin: 0.2–0.4 mg/kg oral daily (feline-adjusted dose) (use injectable formulation given orally). Monitor for CNS signs in cats (ivermectin caution).

4

Weeks 8–12+ — Long-Term

Ongoing Protocol & Quality of Life

🐾 Owner Observation

Continue as long as quality of life is maintained. The goal is life quality over quantity. Appetite, comfort, and engagement are the key metrics. Report any sudden decline immediately.

🔬 Biological Marker

Full restaging at Week 8 and 12. Continue TA1 + PNC-27 if stable or responding. TA1 may continue indefinitely. Re-check liver/kidney values monthly. Adjust doses based on clinical response and tolerance.

04

GHK-Cu

0.25–1 mg/day — monitor hepatic function (copper sensitivity)

EmergingResearch compoundWound

Dose	Route	Frequency	Duration
0.25–1 mg/day or topical	SQ Topical	Daily or 3×/wk	2–4 wk (inj)

Copper Toxicity

Cats are highly sensitive to copper accumulation. Monitor hepatic function. Topical preferred. Avoid with hepatic disease or active cancer.

📋 Example Protocol — See Cycling Guide for break schedules

Example Research Protocol — Feline GHK-Cu (Topical Preferred)

1

Days 1–7 — Initiation

Begin Topical and/or Injectable

🐾 Owner Observation

Apply topical GHK-Cu cream 2×/day to wound or affected skin. If injectable: SQ 0.25–0.5 mg/day in lateral body wall. Monitor eating and litter box — watch for signs of copper sensitivity.

🔬 Biological Marker

Baseline liver panel — cats are copper-sensitive. Topical: minimal systemic absorption, safe for extended use. Injectable: start at 0.25 mg/day. GHK-Cu is reported to activate collagen synthesis and tissue remodeling genes within 48–72 hrs.

2

Weeks 2–4 — Active Remodeling

Wound Healing Phase

🐾 Owner Observation

Visible wound contraction and new tissue formation. Coat quality improving around treated areas. Cat should be comfortable and grooming normally. If injectable, rotate injection sites diligently.

🔬 Biological Marker

May increase injectable to 1 mg/day if tolerated and liver values stable. Recheck liver panel at Week 2 for injectable route. Topical may continue indefinitely. Watch for hepatic copper accumulation signs.

3

Weeks 4+ — Taper or Continue Topical

Transition

🐾 Owner Observation

Injectable: taper and transition to topical-only by Week 4. Topical can continue for chronic skin conditions. Wound should show mature scar tissue and hair regrowth.

🔬 Biological Marker

Discontinue injectable at Week 4 unless vet-directed extension with hepatic monitoring. Topical GHK-Cu safe for long-term use. Avoid injectable in cats with hepatic disease.

05

PNC-27

Investigated for selective cytotoxicity via membrane HDM-2 binding

PreliminaryResearch-use onlyOncology

Investigated Mechanisms

PNC-27 has been reported to bind membrane-bound HDM-2 (overexpressed on cancer cell surfaces in vitro), forming pores that may cause selective necrosis. Normal cells are reported to lack surface HDM-2 and appear to be spared in preclinical models. In vitro studies suggest activity across multiple cancer types. Intratumoral injection likely most effective for accessible tumors. Level V evidence — highly experimental.

Dose	Route	Frequency	Duration
0.25–1 mg/kg	SQ Intratumoral	2–3× weekly	8–12+ weeks

Level V Evidence

PNC-27 has only in vitro and rodent data. No feline clinical trials exist. Intratumoral injection preferred for accessible tumors (FISS, SCC). Used as part of the Investigational Triple Protocol (TA1 + PNC-27 ± IVM) under direct veterinary supervision only.

06

IGF-1 LR3

0.5–2 mcg/kg/day — contraindicated in hypersomatotropism

PreliminaryResearch-use onlyGrowth

Dose	Route	Frequency	Duration
0.5–2 mcg/kg/day	SQ	Once daily	2–4 weeks

Contraindications

Active cancer, feline hypersomatotropism. Very limited feline data. Use conservatively.

📋 Example Protocol — See Cycling Guide for break schedules

Example Research Protocol — Feline IGF-1 LR3 (Conservative)

1

Week 1 — Start Low

Conservative Initiation

🐾 Owner Observation

Very small SQ injection near injury site. Monitor appetite and blood glucose if diabetic risk. Cats with hypersomatotropism (acromegaly) are contraindicated.

🔬 Biological Marker

Start 0.5 mcg/kg/day SQ. Baseline glucose and IGF-1 levels. Extended half-life of LR3 (~20–30 hrs) means feline doses must be conservative. Monitor for hypoglycemia signs.

2

Weeks 2–3 — Titrate

Assess Response

🐾 Owner Observation

Improved tissue healing at injury site. Watch for any swelling or unusual lumps. Monitor eating and energy levels. Report any excessive hunger or weight gain.

🔬 Biological Marker

May increase to 1–2 mcg/kg/day if tolerated. Monitor blood glucose — IGF-1 LR3 can cause hypoglycemia. Do NOT use in cats with known or suspected tumors — growth factor is associated with promoting proliferation.

3

Week 4 — Mandatory Off-Cycle

Required Break

🐾 Owner Observation

Discontinue for minimum 4 weeks. Continue monitoring during off-cycle. Resume only if needed and tolerated.

🔬 Biological Marker

Mandatory 4-week off-cycle to allow IGF-1R receptor recovery. Max 3 total cycles. Recheck blood glucose. Do NOT stack with MGF — overlapping growth factor pathways.

07

MGF (IGF-1Ec)

1–3 mcg/kg/day — inject near injury site

PreliminaryResearch-use onlyGrowth

Dose	Route	Frequency	Duration
1–3 mcg/kg/day	IM SQ	Daily or EOD	2–4 weeks

📋 Example Protocol — See Cycling Guide for break schedules

Example Research Protocol — Feline MGF (Localized Repair)

1

Week 1 — Initiation

Near-Injury Injection

🐾 Owner Observation

IM or SQ injection as close to injury site as possible. Very small volume. Monitor for limping or injection site pain. Cat may be slightly sore at injection site for 1–2 hours.

🔬 Biological Marker

1–3 mcg/kg/day IM near injury. MGF is reported to activate satellite cells for muscle regeneration. Short half-life (~15 min) so inject directly at target tissue for best localized effect.

2

Weeks 2–3 — Active Regeneration

Tissue Rebuilding

🐾 Owner Observation

Improved limb use, less guarding. Cat may begin bearing weight more normally on affected limb. Maintain reduced activity — no jumping from heights during healing.

🔬 Biological Marker

Continue 1–3 mcg/kg daily or EOD. Satellite cell proliferation and muscle fiber regeneration are expected during this phase. May reduce to EOD at Week 3 if improved.

3

Weeks 3–4 — Taper

Discontinue

🐾 Owner Observation

Near-normal function expected. Gradual return to normal activity. Discontinue once healing confirmed.

🔬 Biological Marker

Taper to EOD then discontinue. Short courses preferred — limited feline data. Do NOT stack with IGF-1 LR3 (overlapping pathways). Max 4 weeks total.

08

Fenbendazole

25–50 mg/kg oral, 3 days on / 4 days off — conservative feline dosing

EmergingFDA-approved anthelminticOncology

Investigated Mechanisms

Same proposed mechanisms as canine — microtubule destabilization, p53 activation, and glucose metabolism disruption have been observed in preclinical studies. Feline dosing is more conservative due to smaller body mass and limited hepatic glucuronidation capacity (UGT1A6 deficiency). Administer orally with food.

Dose	Route	Schedule	Duration	Notes
25–50 mg/kg/day	Oral	3 days on / 4 days off	4–12+ weeks	Start at 25 mg/kg; increase if tolerated. Monitor liver values.

Feline Note

Cats have limited glucuronidation capacity. Start at lower dose (25 mg/kg) and monitor liver function closely. Administer with food for improved absorption. Liquid Panacur (100 mg/mL) allows precise feline dosing.

📋 Example Protocol — See Cycling Guide for break schedules

Example Research Protocol — Feline Fenbendazole (Oral Investigational)

1

Week 1 — Initiation

Begin 3-On/4-Off

🐾 Owner Observation

Mix liquid Panacur (100 mg/mL) into food. Start at 25 mg/kg — for a 5 kg cat, that's 1.25 mL. Give with a fatty meal. Monitor appetite, stool, and energy. Most cats tolerate well.

🔬 Biological Marker

25 mg/kg/day oral for 3 consecutive days, then 4 days off. Baseline CBC and liver panel. Cats have limited glucuronidation — start conservative. Fenbendazole is lipophilic with low oral bioavailability — direct GI exposure is highest.

2

Weeks 2–4 — Assess & Titrate

Monitor Tolerance

🐾 Owner Observation

Continue weekly cycling. Watch for appetite loss, lethargy, or vomiting — these may indicate liver stress. If well tolerated after 2 weeks, vet may increase to 50 mg/kg.

🔬 Biological Marker

Recheck CBC and liver panel at Week 2. If liver enzymes stable and tolerated, may increase to 50 mg/kg. Monitor for bone marrow suppression (rare at cycled doses). Tumor assessment at Week 4 if applicable.

3

Weeks 4–12+ — Ongoing

Long-Term Protocol

🐾 Owner Observation

Continue 3-on/4-off as long as quality of life is maintained. The weekly break allows liver recovery. Can combine with TA1 for immune support.

🔬 Biological Marker

Monthly CBC and liver panel. May combine with TA1 (investigated for immune modulation) and/or PNC-27 (investigated for selective tumor targeting). Avoid combining with vincristine — overlapping microtubule mechanism. Some practitioners add curcumin and vitamin E as supportive adjuncts (limited evidence).

09

Ivermectin

0.2–0.4 mg/kg oral — multiple pathways under investigation — EXTREME CAUTION in cats

EmergingFDA-approved antiparasiticOncology

Investigated Mechanisms

Same proposed multi-pathway mechanisms as canine are under investigation: Wnt/β-catenin modulation, Akt/mTOR pathway interference, PAK1 kinase modulation, autophagy induction, and cancer stem cell targeting have been reported in preclinical models. However, cats are more sensitive to ivermectin neurotoxicity than dogs. No feline MDR1 test available — dose conservatively. Maximum feline dose: 0.4 mg/kg (lower ceiling than canine 0.6 mg/kg).

Dose	Route	Frequency	Duration	Indications
0.2–0.4 mg/kg/day	Oral	Daily or 5 on / 2 off	4–12+ weeks	Investigational — lymphoma, FISS, mammary under study

Extreme Caution

Cats are more sensitive to ivermectin neurotoxicity than dogs. Start at 0.2 mg/kg and titrate slowly. Monitor for CNS signs: ataxia, mydriasis, tremors, hypersalivation. Use injectable formulation given orally for precise dosing. Do NOT use topical high-concentration formulations. Lower dose ceiling than canine protocol.

📋 Example Protocol — See Cycling Guide for break schedules

Example Research Protocol — Feline Ivermectin (Investigational — Extreme Caution)

1

Week 1 — Very Low Start

Cautious Initiation

🐾 Owner Observation

Start at lowest dose — 0.2 mg/kg oral. Use injectable formulation (10 mg/mL) given by mouth for precise measurement. Give with food. Monitor closely for neurological signs: unsteadiness, drooling, dilated pupils, tremors.

🔬 Biological Marker

0.2 mg/kg/day oral. Cats are more sensitive to ivermectin neurotoxicity than dogs. No MDR1 test available for cats — proceed with extreme caution. Baseline CBC, liver, neuro exam.

2

Weeks 2–4 — Gradual Increase

Monitor & Titrate

🐾 Owner Observation

If no CNS signs, may increase to 0.3 mg/kg. Continue daily monitoring for any neurological changes. Appetite and normal behavior are positive signs.

🔬 Biological Marker

Maximum feline dose: 0.4 mg/kg/day. Wnt/β-catenin and Akt/mTOR modulation have been reported as dose-dependent in published studies. Recheck CBC at Week 2. May use 5-on/2-off schedule for periodic breaks. Liver monitoring monthly.

3

Weeks 4–12+ — Ongoing

Long-Term Adjunct

🐾 Owner Observation

Continue at tolerated dose. Quality of life is the primary endpoint. Any sudden neurological change → discontinue immediately and contact vet.

🔬 Biological Marker

Monthly monitoring. Can combine with TA1 + fenbendazole for multi-pathway cancer approach. Ivermectin is investigated for Wnt/mTOR pathway modulation while fenbendazole is studied for microtubule disruption and glucose metabolism interference — complementary mechanisms. Do NOT combine with P-glycoprotein inhibitors.

Equine Academy

Equine Protocols

Performance recovery and therapeutic protocols for horses. Doses calculated via BSA allometric scaling. Includes doping/competition awareness.

01

BPC-157

10–20 mcg/kg/day (~5–10 mg for 500 kg) — near injury site

EmergingFDA Cat. 2 · Vet unrestrictedRegen

Investigated Mechanisms

Investigated for promoting healing through increased blood vessel growth (VEGF/eNOS pathway) and inflammation reduction. Studied for tendon-to-bone healing acceleration and gut lining protection (gastric ulcers common in performance horses). Equine dosing at 10–20 mcg/kg/day scaled from canine PK data. Published canine bioavailability: 45–51% IM. No toxic dose found even at repeated high amounts.

Dose	Route	Frequency	Duration	Indications
10–20 mcg/kg/day ~5–10 mg for 500 kg	SQ IM	Once daily	4–8 weeks	Tendon/ligament, joint repair, gastric ulcers, soft tissue

Competition Note

BPC-157 detectable in urine up to 4 days by mass spectrometry. Check governing body rules before treating competition horses.

📋 Example Protocol — See Cycling Guide for break schedules

Example Research Protocol — Equine BPC-157 (Tendon/Joint/GI)

1

Days 1–7 — Initiation

Begin Daily Injection

🐾 Owner Observation

SQ or IM injection near injury site. For a 500 kg horse, that's 5–10 mg/day — larger volume than small animals. Monitor injection site for swelling. Horse should be on reduced work during treatment.

🔬 Biological Marker

10–20 mcg/kg/day SQ or IM near injury. ~5–10 mg total for 500 kg horse. VEGF and eNOS pathway activation has been reported to begin within hours in preclinical models. For gastric ulcers: SQ injection (systemic absorption). Published dog PK data shows 45–51% bioavailability IM — equine PK not established.

2

Weeks 2–4 — Active Healing

Tissue Repair Phase

🐾 Owner Observation

Reduced lameness, less heat at injury. Horse moving more freely. For gastric cases: improved appetite and reduced colic signs. Continue daily injection with site rotation.

🔬 Biological Marker

Maintain 10–20 mcg/kg/day. Angiogenesis and collagen synthesis are expected to be contributing to repair during this phase. Ultrasound at Week 2 for tendon/ligament cases — expect improved fiber pattern. May combine with TB-500 (Wolverine Protocol equivalent) for complementary tissue repair.

3

Weeks 4–8 — Completion

Taper & Return to Work

🐾 Owner Observation

Gradual return to work — walk → trot → canter progression. Monitor for regression. Discontinue once imaging confirms healing.

🔬 Biological Marker

Taper to EOD at Week 4, then 3×/week through Week 6–8. Competition note: BPC-157 detectable in equine urine up to 4 days. Allow washout before competition. Safe — no toxic dose established.

02

TB-500

10–20 mg/wk divided 2–3 injections — best-studied equine compound

EmergingFDA Cat. 2 · Racing banRegenWound

Investigated Mechanisms

Active fragment LKKTETQ is associated with actin binding, cell migration, and wound repair in preclinical models. Best-studied equine compound — research since early 2000s (thymosin β4 discovered 1960s). Investigated for promoting angiogenesis, collagen deposition, and inflammation reduction. Detectable at ultra-low concentrations in equine urine (0.01 ng/mL), making it a significant doping concern for competition horses.

Loading	Maintenance	Route	Duration	Indications
10–20 mg/wk divided 2–3 injections	5–10 mg q7–10d	IM SQ	Load: 2–4 wk / Maint: 4–12 wk	Tendon/ligament, joint inflammation, muscle recovery

Racing Ban

TB-500 will cause positive doping test. Detectable at 0.01 ng/mL in equine urine after single 10 mg dose. Contraindicated with active cancer.

📋 Example Protocol — See Cycling Guide for break schedules

Example Research Protocol — Equine TB-500 (Performance Recovery)

1

Weeks 1–2 — Loading Phase

High-Dose Initiation

🐾 Owner Observation

Administer IM in lateral neck or pectoral. Divide 10–20 mg into 2–3 injections/week. Monitor for injection site reactions. Horse should remain on reduced workload during loading.

🔬 Biological Marker

Baseline ultrasound of injury. 10–20 mg/wk IM divided doses. Actin-binding and LKKTETQ-driven cell migration are reported to begin within 24–48 hrs in preclinical studies. Published equine PK: detectable in urine at 0.01 ng/mL — withdrawal 30+ days before competition.

2

Weeks 3–4 — Transition

Reduce to Maintenance

🐾 Owner Observation

Improved gait, reduced heat/swelling at injury. Horse may show increased willingness during light work. Begin controlled hand-walking/trotting per rehab plan.

🔬 Biological Marker

Reduce to 5–10 mg q7–10d. Re-ultrasound at Week 4 — expect improved fiber pattern. Collagen cross-linking and angiogenesis are expected during this phase. May combine with BPC-157 for complementary effect.

3

Weeks 5–12 — Maintenance & Rehab

Gradual Return to Work

🐾 Owner Observation

Progressive return to work schedule. Walk → trot → canter → full work over 6–8 weeks. Monitor for any regression (heat, lameness). Report immediately.

🔬 Biological Marker

Continue 5–10 mg weekly. Serial ultrasound at Weeks 8 and 12. Fiber alignment and cross-sectional area should be improving. Taper and discontinue once imaging confirms repair. Allow 30+ days clearance before competition.

03

Thymosin Alpha-1

0.5–1.6 mg 2–3×/wk — vaccine adjuvant, immune support

Good EvidenceZadaxin® 35+ countriesImmune

Investigated Mechanisms

Reported to bind TLR2/TLR9, activating NK cells, CD4+/CD8+ T-cells, dendritic cells, and IFN-γ/IL-2 production in published studies. Immunomodulatory — investigated for rebalancing rather than suppressing or overstimulating immune function. Of particular research interest for equine sarcoid and melanoma. Investigated as vaccine adjunct. Published data suggests it does not appear to promote tumor growth.

Dose	Route	Frequency	Duration	Indications
0.5–1.6 mg	SQ IM	2–3× weekly	4–8 weeks	Immune support, chronic infections, vaccine adjuvant

Research Note

Published data suggests TA1 may enhance immune surveillance without appearing to promote tumor growth based on published data — one of the exceptions to the cancer contraindication common among growth-promoting peptides. Investigated in combination with PNC-27 and/or fenbendazole for equine immune-oncology approaches.

📋 Example Protocol — See Cycling Guide for break schedules

Example Research Protocol — Equine Thymosin Alpha-1 (Immune Support)

1

Week 1 — Immune Priming

Begin TA1

🐾 Owner Observation

SQ injection in lateral neck. 0.5–1.6 mg 3×/week. Horse should tolerate well — no common side effects. May notice slight increase in energy after first week.

🔬 Biological Marker

0.5–1.6 mg SQ 2–3×/week. TA1 is reported to activate dendritic cells, NK cells, and CD8+ T-cells via TLR2/TLR9. Immune priming has been reported to begin within 48 hours. Investigated as vaccine adjuvant — in human protocols, administered 24 hrs before vaccination (equine timing not established).

2

Weeks 2–4 — Immune Activation

Full Response

🐾 Owner Observation

Improved recovery from illness, better wound healing, stronger vaccine responses. Horse with chronic infections may show improved appetite and weight maintenance.

🔬 Biological Marker

Continue 2–3×/week. For cancer (sarcoid, melanoma): combine with PNC-27 and/or fenbendazole. TA1 is investigated for immune surveillance support while other agents are studied for direct tumor cell targeting. No desensitization has been observed at therapeutic doses.

3

Weeks 4–8+ — Maintenance

Ongoing or Taper

🐾 Owner Observation

For acute illness: taper and discontinue once resolved. For cancer/chronic conditions: may continue long-term per vet judgment. Monitor overall condition and bloodwork.

🔬 Biological Marker

Recheck CBC with differential — lymphocyte profiles should improve. May continue 1–2×/week for maintenance. Approved for long-term use in humans as Zadaxin® in 35+ countries. Low risk profile.

04

GHK-Cu

2–5 mg/day injectable or topical for wound/hoof care

EmergingResearch compoundWound

Dose	Route	Frequency	Duration
2–5 mg/day or topical	SQ IM Topical	Daily (inj) / 2× daily (topical)	4–12 weeks

Copper Monitoring

Monitor hepatic function with injectable route. Topical preferred for localized conditions. Avoid injectable GHK-Cu in horses with hepatic disease. No competition concerns with topical application.

📋 Example Protocol — See Cycling Guide for break schedules

Example Research Protocol — Equine GHK-Cu (Wound & Hoof)

1

Days 1–7 — Begin Treatment

Topical and/or Injectable

🐾 Owner Observation

Apply topical GHK-Cu cream 2×/day to wounds, hoof cracks, or skin lesions. For injectable: SQ 2–5 mg/day near wound site. Monitor wound bed for healthy granulation tissue.

🔬 Biological Marker

Topical for surface wounds; injectable for deeper tissue. GHK-Cu has been reported to modulate 4,000+ genes related to collagen remodeling in published genomic studies. Equine hoof and wound applications are well-suited — large surface areas benefit from topical approach.

2

Weeks 2–6 — Active Remodeling

Tissue Regeneration

🐾 Owner Observation

Wound contraction, improved hoof wall growth, reduced proud flesh formation. Clean granulation tissue visible. Continue topical application 2×/day.

🔬 Biological Marker

Injectable route: recheck liver values at Week 4 (copper accumulation). Topical may continue indefinitely. Collagen cross-linking and neovascularization expected to be active during this phase. Published canine wound study (Canapp 2003) showed accelerated healing.

3

Weeks 6–12 — Completion

Mature Healing

🐾 Owner Observation

Wound fully epithelialized. Hoof defect growing out. Transition to topical-only maintenance if needed.

🔬 Biological Marker

Discontinue injectable by Week 8 unless vet-directed. Topical safe for long-term use. No competition concerns with topical application.

05

PNC-27

2–5 mg 2–3×/wk for sarcoid, melanoma, SCC

PreliminaryResearch-use onlyOncology

Investigated Mechanisms

PNC-27 has been reported to bind membrane-bound HDM-2 (overexpressed on cancer cell surfaces in vitro), forming pores that may cause selective necrosis. Normal cells are reported to lack surface HDM-2 and appear to be spared in preclinical models. Of particular research interest for equine sarcoids and melanomas — common equine tumors with limited treatment options. Level V evidence — highly experimental.

Dose	Route	Frequency	Duration
2–5 mg	SQ Intratumoral	2–3× weekly	8–12 weeks

Level V Evidence

In vitro/rodent only. No companion animal or equine clinical trials for PNC-27. Intratumoral injection likely most effective for accessible sarcoids. Highly experimental — use only under direct veterinary supervision.

📋 Example Protocol — See Cycling Guide for break schedules

Example Research Protocol — Equine PNC-27 (Investigational)

1

Week 1 — Baseline & Start

Initiate Treatment

🐾 Owner Observation

SQ or intratumoral injection 2–3×/week. For sarcoids: inject directly into or adjacent to lesion if accessible. Monitor for injection site reaction.

🔬 Biological Marker

2–5 mg SQ or intratumoral 2–3×/week. Baseline imaging and tumor measurements. PNC-27 has been reported to bind membrane-bound HDM-2 on cancer cells, potentially inducing pore formation and selective necrosis in preclinical models. Normal cells are reported to lack surface HDM-2.

2

Weeks 4–6 — Response Assessment

Tumor Evaluation

🐾 Owner Observation

Sarcoids may begin to necrose, ulcerate, or shrink. Melanomas may soften. Document changes with photos. Tumor necrosis is a positive sign.

🔬 Biological Marker

Re-image tumors. Compare dimensions. Combine with TA1 (investigated for immune-mediated support) and/or fenbendazole (investigated for metabolic interference). PNC-27 is investigated for direct tumor targeting while TA1 is reported to enhance immune surveillance.

3

Weeks 8–12+ — Ongoing

Continue If Responding

🐾 Owner Observation

Continue as long as tumor is responding and horse is comfortable. Quality of life is primary endpoint.

🔬 Biological Marker

Re-stage at Week 8 and 12. PNC-27 is Level V evidence (in vitro/preclinical). No established equine clinical trials. Continue if clinical improvement observed. No toxic dose established in animal models.

06

IGF-1 LR3

10–50 mcg/day IM near injury — musculoskeletal recovery

PreliminaryResearch-use onlyGrowth

Dose	Route	Frequency	Duration
10–50 mcg/day	IM (near injury)	Once daily	4–6 weeks

Contraindicated with Active Cancer

Do NOT use in horses with known or suspected tumors. IGF-1 is associated with promoting cell proliferation. Monitor blood glucose — can cause hypoglycemia. Cycle 4 wk on / 4 wk off mandatory. Level V evidence for musculoskeletal repair.

📋 Example Protocol — See Cycling Guide for break schedules

Example Research Protocol — Equine IGF-1 LR3 (Musculoskeletal)

1

Week 1 — Initiation

Near-Injury IM Injection

🐾 Owner Observation

IM injection near injury site — tendon, ligament, or muscle. Horse should be on stall rest or reduced work. Monitor for injection site reaction.

🔬 Biological Marker

10–50 mcg/day IM near injury. LR3 variant has extended half-life (~20–30 hrs vs native ~20 min), amplifying local growth factor effect. Start at 10 mcg and titrate. Monitor blood glucose.

2

Weeks 2–4 — Active Phase

Growth Factor Effect

🐾 Owner Observation

Improved gait, reduced lameness. Ultrasound may show increased tissue density at repair site. Continue daily injection.

🔬 Biological Marker

Titrate to 20–50 mcg/day based on response. IGF-1 is reported to promote chondrocyte and fibroblast proliferation. Monitor glucose — IGF-1 can cause hypoglycemia. Do NOT use in horses with suspected tumors.

3

Week 5+ — Mandatory Off-Cycle

Required 4-Week Break

🐾 Owner Observation

Discontinue for 4 weeks minimum. Continue controlled rehab exercise during off-cycle. Monitor for regression.

🔬 Biological Marker

IGF-1R undergoes well-documented downregulation with sustained exposure. Mandatory 4-week off-cycle. Max 3 cycles. Do NOT stack with MGF. Recheck glucose and imaging.

07

MGF (IGF-1Ec)

50–200 mcg/day IM — muscle regeneration & tendon support

PreliminaryResearch-use onlyGrowth

Dose	Route	Frequency	Duration
50–200 mcg/day	IM (near injury)	Daily	4–8 weeks

Short Course Protocol

Limited equine data. Short courses preferred (4–8 weeks max). Do NOT stack with IGF-1 LR3 (overlapping growth factor pathways). Inject as close to injury site as possible for best localized effect.

📋 Example Protocol — See Cycling Guide for break schedules

Example Research Protocol — Equine MGF (Muscle Regeneration)

1

Week 1 — Initiation

Localized IM Injection

🐾 Owner Observation

IM injection into or near damaged muscle. For tendon injuries: inject at musculotendinous junction. Horse on stall rest or controlled walking.

🔬 Biological Marker

50–200 mcg/day IM near injury. MGF is reported to activate satellite cells — the muscle-specific stem cells responsible for regeneration. Short half-life (~15 min) requires local administration for best effect.

2

Weeks 2–4 — Active Regeneration

Satellite Cell Activation

🐾 Owner Observation

Improved muscle tone and reduced atrophy around injury. Horse showing better limb use during controlled exercise.

🔬 Biological Marker

Continue daily or EOD. Satellite cell proliferation and fusion to damaged fibers is expected during this phase. May combine with BPC-157 (investigated for angiogenesis) for comprehensive repair. Ultrasound at Week 4.

3

Weeks 4–8 — Taper

Transition to Rehab

🐾 Owner Observation

Taper to EOD then discontinue. Progressive return-to-work program. Monitor for regression.

🔬 Biological Marker

Maximum 8 weeks. Do NOT stack with IGF-1 LR3 (overlapping pathways). Allow 30+ days clearance before competition if applicable. Re-image at Week 8 to confirm structural improvement.

08

Fenbendazole

50 mg/kg oral, 3 days on / 4 days off — well-established equine safety profile

EmergingFDA-approved anthelminticOncology

Investigated Mechanisms

Same proposed multi-pathway mechanisms under investigation. Fenbendazole has decades of equine safety data as a dewormer (Panacur/Safe-Guard). BSA-scaled dose equivalent to canine. Equine paste formulations allow easy high-volume dosing.

Dose	Route	Schedule	Duration	Indications
50 mg/kg/day ~25g for 500kg horse	Oral	3 days on / 4 days off	4–12+ weeks	Investigated for sarcoid, melanoma, SCC

Competition Note

Check governing body rules. Fenbendazole may be detectable in testing. Monitor liver values with extended use.

📋 Example Protocol — See Cycling Guide for break schedules

Example Research Protocol — Equine Fenbendazole (Oral Investigational)

1

Week 1 — Initiation

Begin 3-On/4-Off

🐾 Owner Observation

Administer oral paste (Safe-Guard/Panacur). For a 500 kg horse at 50 mg/kg, that's 25 grams/day — approximately 5 standard equine deworming tubes per treatment day. Give with grain for absorption. Monitor appetite and manure.

🔬 Biological Marker

50 mg/kg/day oral for 3 consecutive days, then 4 days off. Fenbendazole has decades of equine safety data at deworming doses. Cancer protocol uses higher frequency (weekly cycling) but same per-dose amount. Baseline CBC and liver panel.

2

Weeks 2–4 — Monitor

Assess Tolerance

🐾 Owner Observation

Continue weekly cycling. Horse should maintain normal appetite and energy. Monitor manure consistency. For sarcoids or melanomas: document tumor size with photos.

🔬 Biological Marker

Recheck CBC at Week 2. Monitor liver values. Equine-specific safety data for extended cycling is limited but deworming safety profile is extensive. Tumor assessment at Week 4.

3

Weeks 4–12+ — Ongoing

Long-Term Protocol

🐾 Owner Observation

Continue as long as tolerated and tumor responding. Quality of life and competition schedule are considerations.

🔬 Biological Marker

Monthly bloodwork. May combine with TA1 (investigated for immune modulation) and/or ivermectin (investigated for Wnt/mTOR modulation). Competition note: fenbendazole may be detectable — check governing body rules.

09

Ivermectin

0.3–0.6 mg/kg oral — multiple pathways under investigation, extensive equine safety history

EmergingFDA-approved antiparasiticOncology

Investigated Mechanisms

Investigated for modulating Wnt/β-catenin (observed to interfere with nuclear translocation in vitro), Akt/mTOR signaling, PAK1 kinase, autophagy induction, and cancer stem cell targeting in preclinical models. Ivermectin has the longest equine safety record of any antiparasitic. Standard deworming dose (0.2 mg/kg) is well below the investigational oncology dose (0.3–0.6 mg/kg). No MDR1 gene concerns in horses.

Dose	Route	Frequency	Duration	Indications
0.3–0.6 mg/kg/day	Oral	Daily or 5 on / 2 off	4–12+ weeks	Investigated for sarcoid, melanoma, SCC

Equine Safety

Ivermectin has the longest equine safety track record of any antiparasitic. Standard deworming dose (0.2 mg/kg) is well below investigational oncology dose. Oral paste formulations are convenient for equine dosing. No MDR1 concerns in horses.

📋 Example Protocol — See Cycling Guide for break schedules

Example Research Protocol — Equine Ivermectin (Oral Investigational)

1

Week 1 — Initiation

Begin Oral Protocol

🐾 Owner Observation

Oral paste (1.87% equine formulation). Start at 0.3 mg/kg — slightly above standard deworming dose (0.2 mg/kg). Give with feed. Ivermectin has the longest equine safety record of any antiparasitic.

🔬 Biological Marker

0.3 mg/kg/day oral. Ivermectin is investigated for Wnt/β-catenin, Akt/mTOR, and PAK1 pathway modulation in cancer cells. No MDR1 concerns in horses. Standard deworming dose well-tolerated — cancer dose is modestly higher with daily administration.

2

Weeks 2–4 — Titrate

Increase to Target

🐾 Owner Observation

If tolerated, increase to 0.4–0.6 mg/kg. Monitor appetite, manure, and tumor response. Horse should maintain normal energy and weight.

🔬 Biological Marker

Titrate based on tolerance. May use 5-on/2-off schedule. Combine with fenbendazole for multi-pathway approach — ivermectin is investigated for signaling pathway modulation while fenbendazole is studied for microtubule disruption and glucose metabolism interference. Complementary mechanisms.

3

Weeks 4–12+ — Ongoing

Long-Term Adjunct

🐾 Owner Observation

Continue at tolerated dose. Document tumor response with photos and measurements. Competition horses: allow washout period per governing body rules.

🔬 Biological Marker

Monthly CBC and liver panel. Triple combination (Ivermectin + Fenbendazole + TA1) is investigated for targeting four proposed pathways: Wnt/mTOR modulation + microtubule disruption + glucose metabolism interference + immune engagement.

Multi-Compound Research

How Do Combination Protocols Work?

Some compounds may have complementary effects when administered together based on their investigated mechanisms. Each component in the protocols below addresses a different biological pathway, reducing redundancy and potentially broadening therapeutic coverage.

Regeneration Protocol

Wolverine Protocol

BPC-157+TB-500

Rationale: BPC-157 is investigated for promoting angiogenesis via VEGF upregulation and modulating the NO system. TB-500 is associated with actin-based cell migration and collagen deposition in preclinical studies. Together, they cover vascular repair (BPC-157) and structural tissue remodeling (TB-500) — two distinct but complementary healing pathways.

How to administer: Run both peptides concurrently. BPC-157 is administered daily (SQ near injury or systemic). TB-500 is administered 2×/week during loading, 1×/week during maintenance. They can be injected on the same day at different sites, or alternated (e.g., BPC-157 daily, TB-500 on Mon/Thu). Do not mix in the same syringe — draw and inject separately.

Key Consideration

TB-500 is contraindicated with active cancer. Screen all patients before initiating. BPC-157 alone is a valid alternative for cancer patients needing tissue repair.

Species: All (canine, feline, equine) — adjust doses per species-specific tables above.

Wound Healing Protocol

GLOW Protocol

GHK-Cu+BPC-157+TB-500

Rationale: Adds GHK-Cu's copper-dependent gene activation (4,000+ genes) for collagen remodeling and skin regeneration on top of the Wolverine base. GHK-Cu is particularly studied for surface-level wound healing, skin/coat quality, and scar prevention, while BPC-157 and TB-500 handle deeper tissue and vascular repair.

How to administer: GHK-Cu can be applied topically (2×/day to wound site) and/or injected SQ (daily or 3×/wk). BPC-157 and TB-500 are administered per the Wolverine protocol above. Topical GHK-Cu does not count against injection site rotation. For injectable: use a separate injection site from BPC-157/TB-500.

Contraindications

TB-500: contraindicated with active cancer. GHK-Cu injectable: monitor liver values (copper accumulation). Avoid in Bedlington Terriers and breeds with copper storage disease. Cats: use conservative GHK-Cu doses with hepatic monitoring.

Species: Best established in canine and equine. Feline: use with caution due to copper sensitivity — topical preferred over injectable GHK-Cu.

Oncology Protocol — Highly Experimental

Investigational Triple Protocol

TA1+PNC-27±Ivermectin

Rationale: Three distinct investigational mechanisms targeting different pathways. TA1 is reported to activate NK cells and CD8+ T-cells for immune surveillance (PTEN/PI3K/Akt/mTOR pathway modulation observed in vitro). PNC-27 has been observed to bind membrane-bound HDM-2 on cancer cells and may induce selective pore formation — normal cells appear to be unaffected in preclinical models. Ivermectin (repurposed antiparasitic) is investigated for Akt/mTOR and Wnt signaling modulation, representing a third independent pathway under study.

How to administer: Stagger injections across the week:

Mon / Wed / Fri: TA1 — SQ, lateral body wall
Tue / Thu: PNC-27 — SQ or intratumoral (if accessible)
Daily: Ivermectin — oral (use injectable formulation given by mouth)

Do not combine TA1 and PNC-27 in the same syringe. Ivermectin is oral only. Start TA1 alone for 1 week before adding PNC-27 to establish immune priming. Ivermectin is added at Week 4 if tolerated.

Safety

All three components are Level V evidence (in vitro/rodent only for PNC-27). Ivermectin in cats: use with extreme caution — some breeds have MDR1 gene sensitivity. Never combine with BPC-157/TB-500 in cancer patients — both are associated with promoting angiogenesis and cell migration.

Species: Developed primarily for feline cancer (FISS, lymphoma, FIV-associated). Applicable to canine and equine (sarcoid, melanoma) with dose adjustments.

Comprehensive Oncology Protocol — Highly Experimental

Repurposed Drug Investigational Protocol

Fenbendazole+Ivermectin±TA1

Rationale: Fenbendazole and ivermectin are investigated for targeting cancer through distinct but complementary pathways. Fenbendazole has been observed to destabilize microtubules and interfere with cancer cell glucose metabolism (GLUT1/HKII inhibition reported in vitro). Ivermectin is studied for Wnt/β-catenin, Akt/mTOR, and PAK1 pathway modulation — different targets entirely. Adding TA1 may provide immune activation (NK cells, CD8+ T-cells reported in published studies) for a three-pronged investigational approach: structural disruption + metabolic interference + immune engagement.

How to administer: Both are oral — can be given with the same fatty meal for improved absorption. TA1 is SQ injection on alternating days. Stagger:

Mon / Tue / Wed: Fenbendazole 50 mg/kg oral (3-on period)
Daily: Ivermectin 0.3–0.6 mg/kg oral (or 5 on / 2 off)
Mon / Wed / Fri: TA1 50–100 mcg/kg SQ

Safety

MDR1 test mandatory for ivermectin in dogs. Monthly CBC and liver panel required. Do NOT combine fenbendazole with vincristine/paclitaxel (overlapping mechanisms). All components are experimental for oncology use. Veterinary supervision required.

Species: Canine (with MDR1 clearance), Equine, Feline (reduced ivermectin dose with extreme caution).

Important: Never Mix in the Same Syringe

Peptides should always be drawn and injected separately. Mixing peptides in a single syringe can cause aggregation, degradation, or unpredictable interactions. Use separate syringes, separate injection sites, and rotate sites per the Injection Site Guide.

Administration Reference

Where Should I Inject?

Visual reference for subcutaneous (SQ), intramuscular (IM), topical, and intratumoral injection sites by species. Always consult your veterinarian for proper technique training before administering any injectable. Note: Fenbendazole and Ivermectin are given orally — see species-specific sections for details.

SQ — Subcutaneous

IM — Intramuscular

Topical

IT — Intratumoral

🐕 Canine

1

SQ — Scruff of Neck

Interscapular / Dorsal Neck

Most common SQ site. Tent skin between shoulder blades, insert needle into skin fold at 45°. Good for BPC-157, TA1, TB-500. Use 25–27G needle, 0.5–1 mL max per site.

2

SQ — Lateral Thorax

Ribcage / Chest Wall

Loose skin along ribs. Good rotation site for daily protocols. Tent skin away from body, inject into fold. Alternate sides each day.

3

SQ — Flank Fold

Lateral Abdominal Skin Fold

Inguinal/flank fold — abundant loose skin. Ideal for larger volume injections. Rotate left/right daily.

4

IM — Rear Thigh

Quadriceps / Semimembranosus

Primary IM site for dogs. Palpate muscle belly, insert 22–25G needle perpendicular. For MGF, IGF-1 LR3, or BPC-157 near injury. Aspirate before injecting.

5

IM — Lumbar Epaxial

Longissimus / Spinal Muscles

For localized spinal or back injuries. Use for BPC-157 targeting lumbar disc issues. Insert into muscle mass lateral to spine.

🐈 Feline

1

SQ — Lateral Trunk (Preferred)

Lateral Thorax / Abdominal Wall

⚠️ Preferred over scruff for cats. FISS (Feline Injection-Site Sarcoma) risk is higher interscapularly. Inject along lateral body wall with rotating sites. Use 25–27G needle.

2

SQ — Right Lateral Chest

Right Ribcage Skin Fold

Rotate with left side. Tent skin, insert at shallow 30–45° angle. Good for BPC-157, TA1 daily dosing.

3

SQ — Left Lateral Flank

Left Abdominal Fold

Alternate with right side chest. Keep injection volume small (<0.5 mL per site for cats).

4

IM — Rear Thigh

Quadriceps Muscle

Only IM site for most cats. Use 25G needle, small volume (<0.3 mL). For BPC-157 targeting hind limb injuries or MGF. Aspirate before injecting.

⚠ FISS Warning: Feline Injection-Site Sarcoma risk is elevated with repeated interscapular (scruff) injections. Use lateral body wall sites and rotate aggressively. Record injection sites and dates. If any firm lump develops at an injection site and persists >3 months, grows >2cm, or continues to grow 1 month after injection — seek immediate veterinary evaluation.

🐴 Equine

1

IM — Lateral Neck

Cervical Neck Muscles

Primary IM site for horses. Palpate triangle between nuchal ligament (top), cervical vertebrae (bottom), and scapula (rear). Insert 18–20G × 1.5" needle perpendicular. Up to 20 mL per site.

2

SQ — Lateral Neck

Subcutaneous Neck

Tent skin over lateral neck, inject shallow angle. For TA1, BPC-157 systemic dosing. Use 20–22G needle. Rotate between left and right neck.

3

IM — Pectoral

Pectoral Muscles

Good secondary IM site. For TB-500, BPC-157 targeting forelimb injuries. Insert needle perpendicular into muscle mass.

4

IM — Gluteal / Semimembranosus

Hindquarter Muscles

Large muscle mass for higher volume IM injections. For MGF, IGF-1 LR3 near hind limb injuries. Use caution — avoid sciatic nerve area.

5

IM — Near Injury Site

Localized Injection

For BPC-157, MGF, IGF-1 LR3 — inject IM as close to injury as practical. Particularly useful for tendon/ligament injuries. Must be performed by veterinarian.

Administration Safety

Never reuse needles between injections. Always use a fresh, sterile needle and syringe for each injection. Clean injection sites with alcohol swab before administration. Aspirate (pull back plunger) before all IM injections — if blood appears, withdraw and choose a different insertion point. Record injection sites and rotate daily. Dispose of sharps in an approved sharps container. All injectable peptides should be refrigerated and reconstituted per manufacturer specifications.

Research Consideration

How Should I Cycle Peptides?

Drug targets and compound receptors can undergo desensitization (downregulation) with continuous, prolonged exposure. Scheduled breaks — known as "cycling" — may help maintain receptor responsiveness and therapeutic efficacy. This is an active area of investigation with limited direct veterinary data; the cycling patterns below are extrapolated from pharmacological principles and human clinical use.

Why Cycling Matters

When a receptor is continuously stimulated by its ligand, cells often respond by internalizing receptors (pulling them off the membrane surface) or reducing receptor expression (making fewer). This means the same dose produces a diminishing effect over time — a phenomenon called tachyphylaxis. Scheduled breaks allow receptor populations to recover, restoring sensitivity for the next treatment cycle.

BPC-157

RegenLow risk

BPC-157 acts primarily through VEGF/eNOS signaling pathways. Published data suggests minimal desensitization risk at therapeutic doses, and no toxic dose has been established. However, extended continuous use (>8 weeks) has not been studied in companion animals.

ON 2–4 wk

REST 1 wk

ON 2–4 wk

Suggested: 2–4 weeks on → 1 week off → repeat as needed. May run continuously for acute injuries ≤4 wk.

TB-500

RegenModerate risk

TB-500 is associated with actin polymerization and cell migration. Loading/maintenance structure inherently cycles intensity. Continuous high-dose exposure may theoretically saturate actin-binding sites. Equine studies used finite treatment windows (4–12 weeks) rather than indefinite dosing.

LOAD 2–4 wk

MAINT 4–8 wk

REST 4 wk

Suggested: 2–4 wk loading → 4–8 wk maintenance → 4 wk off before new cycle.

Thymosin Alpha-1

ImmuneLow risk

TA1 is an immunomodulator — it rebalances immune function rather than stimulating a single receptor pathway. Approved for long-term use in 35+ countries as Zadaxin®. Desensitization risk is considered low because it acts through TLR2/TLR9 and modulates dendritic cell maturation rather than directly agonizing a single receptor. Cancer/chronic infection protocols may justify continuous use.

ON 4–12 wk

REST 2–4 wk

Suggested: 4–12 weeks on → 2–4 weeks off. For active cancer or FIV/FeLV: may use continuously per veterinary judgment.

GHK-Cu

WoundLow risk (topical) / Moderate (injectable)

GHK-Cu modulates 4,000+ genes and acts through copper-dependent remodeling pathways rather than a single receptor. Topical use carries minimal desensitization risk and may be used continuously. Injectable use introduces systemic copper, which accumulates — hepatic monitoring is needed for cycles >4 weeks.

INJ 4–8 wk

REST 4 wk

TOPICAL — continuous OK

Injectable: 4–8 wk on → 4 wk off (monitor liver). Topical: continuous for chronic dermatologic conditions.

PNC-27

OncologyUnknown risk

PNC-27 is investigated for targeting membrane-bound HDM-2 on cancer cells — a protein that normal cells do not express on their surface. Because the target is cancer-cell-specific and the mechanism is physical membrane disruption (pore formation), classical receptor desensitization may not apply. However, tumor microenvironment adaptation and HDM-2 expression changes are theoretically possible over time.

ON 8–12 wk

ASSESS

CONTINUE if responding

Suggested: 8–12 weeks continuous → reassess imaging and clinical response → continue if effective. No established cycling protocol.

IGF-1 LR3 & MGF

GrowthHIGH risk

Growth factors carry the highest desensitization risk. IGF-1 receptor (IGF-1R) undergoes well-documented downregulation with sustained exposure. The extended half-life of LR3 (~20–30 hrs vs native ~20 min) amplifies this concern. MGF (IGF-1Ec) has a shorter half-life (~15 min) but is reported to activate satellite cells through similar pathways. Mandatory cycling is strongly recommended.

ON 4 wk

OFF 4 wk

ON 4 wk

Mandatory: 4 weeks on → 4 weeks off. Max 3 cycles. Monitor blood glucose during on-cycles. Do not stack IGF-1 LR3 and MGF simultaneously.

Fenbendazole

OncologyBUILT-IN cycling

Fenbendazole's 3-on/4-off schedule is itself a cycling protocol. The 4-day break allows bone marrow recovery and hepatic clearance. Extended continuous daily dosing has been associated with bone marrow suppression in dogs. The weekly cycling is expected to help prevent receptor desensitization and reduce cumulative toxicity risk.

ON 3 days

OFF 4 days

ON 3 days

OFF 4 days

Built-in: 3 days on → 4 days off weekly. Monitor CBC monthly. May run continuously (with weekly breaks) for 12+ weeks if bloodwork stable.

Ivermectin

OncologyLow desensitization risk

Ivermectin is investigated for modulating multiple pathways (Wnt, Akt/mTOR, PAK1) rather than a single receptor, reducing classical desensitization risk. It has been used as a daily heartworm preventive in dogs for decades with sustained efficacy. For cancer protocols, a 5-on/2-off schedule provides periodic breaks while maintaining consistent pathway modulation.

ON 5 days

OFF 2 days

ON 5 days

OFF 2 days

Suggested: 5 days on → 2 days off, or daily continuous. Monthly liver/CBC monitoring. MDR1 test mandatory before starting in dogs.

Research Note on Multi-Compound Protocols

When running multiple peptides concurrently, stagger injections on different days where practical (e.g., TA1 on Mon/Wed/Fri, PNC-27 on Tue/Thu). This reduces per-day injection burden on the animal and may improve individual peptide absorption. Cycling schedules should be coordinated so not all peptides are interrupted simultaneously — maintain at least one active therapeutic during transition periods. All cycling recommendations here are based on pharmacological principles and should be adjusted based on individual clinical response under veterinary supervision.

Preparation Reference

How Do I Reconstitute Peptides?

Injectable research peptides (BPC-157, TB-500, TA1, GHK-Cu, PNC-27, IGF-1 LR3, MGF) ship as lyophilized (freeze-dried) powder and must be reconstituted with bacteriostatic water before use. Proper reconstitution technique directly affects compound stability, sterility, and accurate dosing.

1

Gather Supplies

You will need: lyophilized peptide vial, bacteriostatic water (BAC water with 0.9% benzyl alcohol), alcohol swabs, insulin syringes (29–31G), and a clean workspace.

BAC water preserves sterility for multi-use over ~28 days. Do not use sterile water (single-use only) or saline unless specifically directed.

2

Clean Vial Tops

Wipe both the peptide vial and BAC water vial rubber stoppers with an alcohol swab. Allow to air dry (~10 seconds). Do not blow on them or touch with fingers after cleaning.

Contamination at this step is the #1 cause of bacterial growth. Work on a clean, flat surface. Wash hands thoroughly or wear gloves.

3

Draw BAC Water

Using an insulin syringe, draw the desired amount of BAC water. Common volumes: 1 mL or 2 mL depending on desired concentration. See table below for reference amounts.

Tip: Pull the plunger back slowly to minimize air bubbles. If bubbles appear, tap the syringe gently and push them out before injecting into the peptide vial.

4

Add Water to Peptide

Insert needle through the peptide vial stopper. Do not spray directly onto the powder. Aim the stream against the glass wall and let water trickle down gently over the powder cake.

Forceful spraying can damage peptide bonds and reduce potency. The powder should dissolve on its own — this typically takes 30–120 seconds. Do not shake.

5

Gently Swirl (Never Shake)

If powder remains after 2 minutes, gently roll or swirl the vial between your palms. The solution should be completely clear with no visible particles or cloudiness.

Shaking denatures peptides by breaking bonds at the air-liquid interface. If solution is cloudy after 5 minutes of gentle swirling, the peptide may be degraded — do not use.

6

Store & Label

Refrigerate immediately at 2–8°C (36–46°F). Label the vial with: peptide name, concentration (mg/mL), reconstitution date, and expiration (28 days from reconstitution).

Never freeze reconstituted peptides. Avoid light exposure. BPC-157 is especially light-sensitive — store in a dark location or wrap vial in foil. Discard after 28 days.

Concentration Formula

Concentration (mg/mL) Injectable only = Peptide Amount (mg) ÷ BAC Water Volume (mL)

Example: 5 mg peptide + 2 mL BAC water = 2.5 mg/mL → each 0.1 mL (10 units on insulin syringe) = 0.25 mg = 250 mcg

Common Reconstitution Reference

Peptide Vial	BAC Water	Concentration	100 mcg =	250 mcg =	500 mcg =	1 mg =
5 mg	1 mL	5 mg/mL	0.02 mL (2 units)	0.05 mL (5 units)	0.10 mL (10 units)	0.20 mL (20 units)
5 mg	2 mL	2.5 mg/mL	0.04 mL (4 units)	0.10 mL (10 units)	0.20 mL (20 units)	0.40 mL (40 units)
10 mg	2 mL	5 mg/mL	0.02 mL (2 units)	0.05 mL (5 units)	0.10 mL (10 units)	0.20 mL (20 units)
10 mg	5 mL	2 mg/mL	0.05 mL (5 units)	0.125 mL (12.5 u)	0.25 mL (25 units)	0.50 mL (50 units)

Standard insulin syringe: 100 units = 1 mL. Each "unit" mark = 0.01 mL.

Storage & Handling

Lyophilized (unreconstituted): Stable at room temperature for shipping, but refrigerate or freeze for long-term storage (months to years at -20°C).
Reconstituted: Refrigerate at 2–8°C. Use within 28 days. Never freeze once reconstituted.
Light sensitivity: BPC-157 and GHK-Cu are particularly light-sensitive — store away from light or wrap vial in aluminum foil.
Drawing doses: Always use a new sterile needle each time you pierce the vial stopper. Insulin syringes (29–31G) are ideal for small-volume dosing.

Scientific Literature

References Cited (38)

All protocols on this site are derived from published, peer-reviewed research. References are organized by species applicability for easy lookup.

He L et al. PK, distribution, metabolism, excretion of BPC 157 in rats and dogs. Front Pharmacol. 2022. PMID 36588722 🐕
Xu C et al. Preclinical safety evaluation of BPC-157. Regul Toxicol Pharmacol. 2020. PMID 32334036 General
Vasireddi N et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine. OJSM. 2025. PMC12313605 General
Gwyer D et al. BPC 157 and musculoskeletal soft tissue healing. Cell Tissue Res. 2019. PMID 30915550 General
Jozwiak M et al. Multifunctionality of BPC 157 — Literature and Patent Review. Pharmaceuticals. 2025. PMC11859134 General
Kleinman HK, Sosne G. Animal studies with thymosin β4. Ann N Y Acad Sci. 2010. PMID 20536453 General
Goldstein AL et al. Thymosin β4: a multi-functional regenerative peptide. Expert Opin Biol Ther. 2012. PMID 22074294 General
Kwok WH et al. Doping control analysis of TB-500 in equine urine/plasma. J Chromatogr B. 2013. PMID 23084823 🐴
Esposito S et al. TB500/TB1000: understanding misbranded drugs. Drug Test Anal. 2022. doi:10.1002/dta.3413 🐴
Philp D, Kleinman HK. Animal studies with thymosin beta 4. Ann N Y Acad Sci. 2010. General
King R, Tuthill C. Immune modulation with thymosin alpha 1. Vitam Horm. 2016. PMID 27450734 General
Dominari A et al. Thymosin alpha 1: comprehensive review. World J Virol. 2020. PMID 33362999 General
Bellet MM et al. Thymosin Alpha1 in Cancer Therapy. Front Oncol. 2019. doi:10.3389/fonc.2019.00873 General
Guo Y et al. TA1 suppresses breast cancer via PTEN/PI3K/Akt/mTOR. Apoptosis. 2015. General
Wang F et al. TA1-Fc with prolonged half-life. Sci Rep. 2018. PMID 30120313 General
Li Y et al. Thymosin α-1 in cancer: immunoregulation. Int Immunopharmacol. 2023. General
Goldspink G. Mechanical signals, IGF-I gene splicing, muscle adaptation. Physiology. 2005. PMID 16174871 General
Pickart L et al. GHK Peptide in Skin Regeneration. BioMed Res Int. 2015. PMC4508379 General
Pickart L, Margolina A. Regenerative Actions of GHK-Cu. Int J Mol Sci. 2018. PMC6073405 General
Canapp SO et al. Topical GHK-Cu on ischemic canine wounds. Vet Surg. 2003. PMID 14569578 🐕
Maquart FX et al. GHK-Cu stimulates connective tissue in rat wounds. J Clin Invest. 1993. PMID 8227350 General
Sarafraz-Yazdi E et al. PNC-27 binds HDM-2, induces membrane-pore formation. Biomedicines. 2022. General
Sarafraz-Yazdi E et al. PNC-27 investigated for selective cytotoxicity via membrane HDM-2. PNAS. 2010. PMID 20080606 General
Sookraj KA et al. PNC-27 induces tumor cell lysis as intact peptide. Cancer Chemother Pharmacol. 2010. PMID 20182728 General
Davitt K et al. PNC-27 induces necrosis of K562 leukemia cells. Ann Clin Lab Sci. 2014. PMID 25117093 General
Pincus MR et al. Poptosis: selective killing of cancer cells. Clin Oncol. 2023. General
JAHVM Case Report: Canine stifle with BPC-157 + TB500. JAHVM. 2023. ahvma.org 🐕
Juarez M et al. Ivermectin: antiparasitic to cancer drug. Am J Cancer Res. 2018. PMID 29344093 General
Dogra N et al. Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death. Sci Rep. 2018;8:11926. PMID 30093705 General
Song B et al. Fenbendazole: An Anticancer Agent? A Case Series of Self-Administration. Case Rep Oncol. 2025;18:856. PMC12215191 General
Nguyen J et al. Oral Fenbendazole for Cancer Therapy in Humans and Animals. Anticancer Res. 2024;44(9):3725–3735. General
Leach B et al. Fenbendazole as a Potential Anticancer Drug. Anticancer Res. 2012. PMC3580766 General
Kim YJ et al. Fenbendazole Exhibits Differential Anticancer Effects In Vitro and In Vivo in Mouse Lymphoma. Curr Issues Mol Biol. 2023;45:8925–8938. PMC10670425 General
Li L et al. Fenbendazole induces pyroptosis in breast cancer cells through HK2/caspase-3/GSDME. Front Pharmacol. 2025;16:1596694. General
Zhu M et al. Ivermectin inhibits canine mammary tumor growth by regulating cell cycle and WNT signaling. BMC Vet Res. 2019;15:238. PMC6679554 🐕
Tang M et al. Ivermectin, a potential anticancer drug derived from an antiparasitic drug. Pharmacol Res. 2021;163:105207. PMC7505114 General
Dominguez-Gomez G et al. Ivermectin as repositioned cancer drug: antitumor effects at clinically feasible concentrations. Cancer Chemother Pharmacol. 2020;85:1153–1163. General
Morinaga S et al. Ivermectin Combined With rMETase Synergistically Eradicates Pancreatic Cancer Cells. Anticancer Res. 2025;45(1):97–103. General

He L et al. PK, distribution, metabolism, excretion of BPC 157 in rats and dogs. Front Pharmacol. 2022. PMID 36588722
Canapp SO et al. Topical GHK-Cu on ischemic canine wounds. Vet Surg. 2003. PMID 14569578
JAHVM Case Report: Canine stifle with BPC-157 + TB500. JAHVM. 2023. ahvma.org
Zhu M et al. Ivermectin inhibits canine mammary tumor growth by regulating cell cycle and WNT signaling. BMC Vet Res. 2019;15:238. PMC6679554

Only 4 of 38 studies include direct canine data. Most protocols are extrapolated from human, rodent, and equine research using allometric BSA scaling (canine Km=20).

No feline-specific studies are included in the current reference set. All feline protocols are extrapolated using allometric BSA scaling (feline Km=12) from canine and rodent PK data. This represents a significant evidence gap and underscores the need for the Outcome Tracker to collect real-world feline outcome data.

Kwok WH et al. Doping control analysis of TB-500 in equine urine/plasma. J Chromatogr B. 2013. PMID 23084823
Esposito S et al. TB500/TB1000: understanding misbranded drugs. Drug Test Anal. 2022. doi:10.1002/dta.3413
Kleinman HK, Sosne G. Animal studies with thymosin β4. Ann N Y Acad Sci. 2010. PMID 20536453

Equine data is strongest for TB-500/Thymosin β4, which has been studied in horses since the early 2000s (thymosin β4 itself was discovered in the 1960s). Doping detection methods are well-established. Other equine protocols use BSA-scaled doses from human/rodent data.

Xu C et al. Preclinical safety evaluation of BPC-157. Regul Toxicol Pharmacol. 2020. PMID 32334036
Vasireddi N et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine. OJSM. 2025. PMC12313605
Gwyer D et al. BPC 157 and musculoskeletal soft tissue healing. Cell Tissue Res. 2019. PMID 30915550
Jozwiak M et al. Multifunctionality of BPC 157 — Literature and Patent Review. Pharmaceuticals. 2025. PMC11859134
Goldstein AL et al. Thymosin β4: a multi-functional regenerative peptide. Expert Opin Biol Ther. 2012. PMID 22074294
King R, Tuthill C. Immune modulation with thymosin alpha 1. Vitam Horm. 2016. PMID 27450734
Dominari A et al. Thymosin alpha 1: comprehensive review. World J Virol. 2020. PMID 33362999
Bellet MM et al. Thymosin Alpha1 in Cancer Therapy. Front Oncol. 2019. doi:10.3389/fonc.2019.00873
Guo Y et al. TA1 suppresses breast cancer via PTEN/PI3K/Akt/mTOR. Apoptosis. 2015.
Goldspink G. Mechanical signals, IGF-I gene splicing, muscle adaptation. Physiology. 2005. PMID 16174871
Pickart L et al. GHK Peptide in Skin Regeneration. BioMed Res Int. 2015. PMC4508379
Pickart L, Margolina A. Regenerative Actions of GHK-Cu. Int J Mol Sci. 2018. PMC6073405
Maquart FX et al. GHK-Cu stimulates connective tissue in rat wounds. J Clin Invest. 1993. PMID 8227350
Sarafraz-Yazdi E et al. PNC-27 binds HDM-2, induces membrane-pore formation. Biomedicines. 2022.
Sarafraz-Yazdi E et al. PNC-27 investigated for selective cytotoxicity via membrane HDM-2. PNAS. 2010. PMID 20080606
Sookraj KA et al. PNC-27 induces tumor cell lysis as intact peptide. Cancer Chemother Pharmacol. 2010. PMID 20182728
Davitt K et al. PNC-27 induces necrosis of K562 leukemia cells. Ann Clin Lab Sci. 2014. PMID 25117093
Pincus MR et al. Poptosis: selective killing of cancer cells. Clin Oncol. 2023.
Juarez M et al. Ivermectin: antiparasitic to cancer drug. Am J Cancer Res. 2018. PMID 29344093
Dogra N et al. Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death. Sci Rep. 2018;8:11926. PMID 30093705
Song B et al. Fenbendazole: An Anticancer Agent? A Case Series of Self-Administration. Case Rep Oncol. 2025;18:856. PMC12215191
Nguyen J et al. Oral Fenbendazole for Cancer Therapy in Humans and Animals. Anticancer Res. 2024;44(9):3725–3735.
Leach B et al. Fenbendazole as a Potential Anticancer Drug. Anticancer Res. 2012. PMC3580766
Kim YJ et al. Fenbendazole Exhibits Differential Anticancer Effects In Vitro and In Vivo in Mouse Lymphoma. Curr Issues Mol Biol. 2023;45:8925–8938. PMC10670425
Li L et al. Fenbendazole induces pyroptosis in breast cancer cells through HK2/caspase-3/GSDME. Front Pharmacol. 2025;16:1596694.
Tang M et al. Ivermectin, a potential anticancer drug derived from an antiparasitic drug. Pharmacol Res. 2021;163:105207. PMC7505114
Dominguez-Gomez G et al. Ivermectin as repositioned cancer drug: antitumor effects at clinically feasible concentrations. Cancer Chemother Pharmacol. 2020;85:1153–1163.
Morinaga S et al. Ivermectin Combined With rMETase Synergistically Eradicates Pancreatic Cancer Cells. Anticancer Res. 2025;45(1):97–103.
Li Y et al. Thymosin α-1 in cancer: immunoregulation. Int Immunopharmacol. 2023.
Philp D, Kleinman HK. Animal studies with thymosin beta 4. Ann N Y Acad Sci. 2010.
Wang F et al. TA1-Fc with prolonged half-life. Sci Rep. 2018. PMID 30120313

Evidence-Based Peptide & Repurposed Drug Protocols for Veterinary Oncology & Recovery

How to Read This Site — Evidence Grading System

Good Evidence

Emerging Evidence

Preliminary / In Vitro Only

Key Terms — A Quick Reference

Which Species Protocols Are Available?

Canine Academy

Feline Academy

Equine Academy

Canine Protocols

Example Research Protocol — Wolverine Protocol (BPC-157 + TB-500)

Example Research Protocol — TB-500

Example Research Protocol — Thymosin Alpha-1 (Immune Modulation)

Example Research Protocol — GHK-Cu (Injectable + Topical)

Example Research Protocol — PNC-27 (Investigational)

Example Research Protocol — IGF-1 LR3 (Growth Factor Cycling)

Example Research Protocol — MGF (Localized Muscle Repair)

Example Research Protocol — Fenbendazole (Oral Investigational)

Example Research Protocol — Ivermectin (Oral Investigational)

Feline Protocols

Example Research Protocol — Feline BPC-157

Example Research Protocol — Feline TB-500

Example Research Protocol — Feline Thymosin Alpha-1 (Standalone Immune Support)

Example Research Protocol — Feline Investigational Triple Protocol (TA1 + PNC-27 ± Ivermectin)

Example Research Protocol — Feline GHK-Cu (Topical Preferred)

Example Research Protocol — Feline IGF-1 LR3 (Conservative)

Example Research Protocol — Feline MGF (Localized Repair)

Example Research Protocol — Feline Fenbendazole (Oral Investigational)

Example Research Protocol — Feline Ivermectin (Investigational — Extreme Caution)

Equine Protocols

Example Research Protocol — Equine BPC-157 (Tendon/Joint/GI)

Example Research Protocol — Equine TB-500 (Performance Recovery)

Example Research Protocol — Equine Thymosin Alpha-1 (Immune Support)

Example Research Protocol — Equine GHK-Cu (Wound & Hoof)

Example Research Protocol — Equine PNC-27 (Investigational)

Example Research Protocol — Equine IGF-1 LR3 (Musculoskeletal)

Example Research Protocol — Equine MGF (Muscle Regeneration)

Example Research Protocol — Equine Fenbendazole (Oral Investigational)

Example Research Protocol — Equine Ivermectin (Oral Investigational)

How Do Combination Protocols Work?

Wolverine Protocol

GLOW Protocol

Investigational Triple Protocol

Repurposed Drug Investigational Protocol

How Do I Calculate the Right Dose?

Dosage Result

Where Should I Inject?

🐕 Canine

Interscapular / Dorsal Neck

Ribcage / Chest Wall

Lateral Abdominal Skin Fold

Quadriceps / Semimembranosus

Longissimus / Spinal Muscles

🐈 Feline

Lateral Thorax / Abdominal Wall

Right Ribcage Skin Fold

Left Abdominal Fold

Quadriceps Muscle

🐴 Equine

Cervical Neck Muscles

Subcutaneous Neck

Pectoral Muscles

Hindquarter Muscles

Localized Injection

How Should I Cycle Peptides?

BPC-157

TB-500

Thymosin Alpha-1

GHK-Cu

PNC-27

IGF-1 LR3 & MGF

Fenbendazole

Ivermectin

How Do I Reconstitute Peptides?

Gather Supplies

Clean Vial Tops

Draw BAC Water

Add Water to Peptide

Gently Swirl (Never Shake)